Literature DB >> 12133747

Risk factors for nephrolithiasis in patients with familial idiopathic hypercalciuria.

Nicolas Lerolle1, Brigitte Lantz, Françoise Paillard, Bernard Gattegno, Antoine Flahault, Pierre Ronco, Pascal Houillier, Eric Rondeau.   

Abstract

PURPOSE: About 40% of patients with nephrolithiasis have idiopathic hypercalciuria, sometimes associated with a family history of kidney stones. In these families, little is known about the frequency of, and risk factors for, stone formation among hypercalciuric patients. We therefore conducted a prospective study of 216 subjects from 33 families with idiopathic hypercalciuria.
MATERIALS AND METHODS: We recorded the age, weight, and history of calcium stones in all subjects, and measured 24-hour urine volume and excretion of calcium, uric acid, sodium, magnesium, urea, citrate, phosphate, and sulfate on a nonrestricted diet. We performed a more complete metabolic evaluation in many of the hypercalciuric subjects (calciuria/weight >0.1 mmol/kg/d). Multivariate logistic regression analysis was performed to identify independent risk factors for stone formation.
RESULTS: The prevalence of self-reported nephrolithiasis was 46% (61/132) in hypercalciuric subjects and 11% (7/63) in normocalciuric subjects (P <0.0001). In multivariate analysis, age (odds ratio [OR] per 10 years of age = 1.3; 95% confidence interval [CI]: 1.1 to 1.6), urine calcium excretion (OR = 1.3 per mmol/d increase; 95% CI: 1.2 to 1.5), and uric acid excretion (OR = 3.3 per mmol/d increase; 95% CI: 1.4 to 7.5) were independent risk factors for nephrolithiasis. The risk of nephrolithiasis increased progressively with greater levels of hypercalciuria.
CONCLUSION: We found a significant dose-effect association between calciuria and stone disease in patients with familial hypercalciuria. Other factors associated with stone formation included higher uric acid excretion, probably reflecting higher food intake, and age, probably reflecting the length of exposure to hypercalciuria and hyperuricosuria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12133747     DOI: 10.1016/s0002-9343(02)01152-x

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

1.  Renal phosphate leak in patients with idiopathic hypercalciuria and calcium nephrolithiasis.

Authors:  Armando Luis Negri; Rodolfo Spivacow; Elisa Del Valle; Erich Fradinger; Alicia Marino; Jose Ruben Zanchetta
Journal:  Urol Res       Date:  2003-09-13

2.  Comparison of Metabolic Risk Factors in Urolithiasis Patients according to Family History.

Authors:  Cheol Park; Yun-Sok Ha; Yong-June Kim; Seok-Joong Yun; Sang-Cheol Lee; Wun-Jae Kim
Journal:  Korean J Urol       Date:  2010-01-21

3.  The calcium-sensing receptor promotes urinary acidification to prevent nephrolithiasis.

Authors:  Kirsten Y Renkema; Ana Velic; Henry B Dijkman; Sjoerd Verkaart; Annemiete W van der Kemp; Marta Nowik; Kim Timmermans; Alain Doucet; Carsten A Wagner; René J Bindels; Joost G Hoenderop
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

4.  Secondary contributors to bone loss in osteoporosis related hip fractures.

Authors:  B J Edwards; C B Langman; A D Bunta; M Vicuna; M Favus
Journal:  Osteoporos Int       Date:  2008-01-08       Impact factor: 4.507

Review 5.  Pharmacological interventions for preventing complications in idiopathic hypercalciuria.

Authors:  Joaquin Escribano; Albert Balaguer; Filomena Pagone; Albert Feliu; Marta Roqué I Figuls
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

6.  Anti-inflammatory effects of royal jelly on ethylene glycol induced renal inflammation in rats.

Authors:  Zeyneb Aslan; Laçine Aksoy
Journal:  Int Braz J Urol       Date:  2015 Sep-Oct       Impact factor: 1.541

Review 7.  The genetic framework for development of nephrolithiasis.

Authors:  Vinaya Vasudevan; Patrick Samson; Arthur D Smith; Zeph Okeke
Journal:  Asian J Urol       Date:  2016-11-28

Review 8.  MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders.

Authors:  Jens Bollerslev; Camilla Schalin-Jäntti; Lars Rejnmark; Heide Siggelkow; Hans Morreau; Rajesh Thakker; Antonio Sitges-Serra; Filomena Cetani; Claudio Marcocci
Journal:  Eur J Endocrinol       Date:  2019-06-01       Impact factor: 6.664

9.  Effects of high doses of cholecalciferol in normal subjects: a randomized double-blinded, placebo-controlled trial.

Authors:  Birgitte Nygaard; Niels Erik Frandsen; Lisbet Brandi; Knud Rasmussen; Ove Vyff Oestergaard; Lars Oedum; Hans Christian Hoeck; Ditte Hansen
Journal:  PLoS One       Date:  2014-08-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.